Search for an orphan drug

* (*) mandatory field

Other search option(s)

Marketing authorization with orphan designation - USA

  • Tradename: DAURISMO
  • ATC code : -
  • EU Number: -
  • MA date : 21/11/2018
  • MA holder: PFIZER, INC.

Therapeutic indication

DAURISMO is indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are >75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.
Limitation of Use: DAURISMO has not been studied in patients with the comorbidities of severe renal impairment or moderate-to-severe hepatic impairment.

The documents contained in this web site are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.